ARCHIMED acquires ZimVie at a premium

2026-01-15

On July 21, 2025, ZimVie Inc. (hereinafter referred to as "ZimVie"), a world-leading provider of dental solutions, announced that it had reached a definitive acquisition agreement with ARCHIMED, a global investment institution focused on the healthcare sector.

ARCHIMED acquires ZimVie at a premium (1)

Pursuant to the agreement, ARCHIMED will acquire all of ZimVie's outstanding and issued shares at a cash consideration of $19.00 per share, with the total transaction valuation amounting to approximately $730 million. The offer represents a premium of 99% over the average closing price of ZimVie's shares in the past 90 trading days. The transaction has been unanimously approved by ZimVie's Board of Directors and is expected to be completed by the end of 2025. Upon completion, ZimVie will become a privately held company and delist from the Nasdaq Stock Market.

ARCHIMED acquires ZimVie at a premium (2)

ZimVie was spun off from Zimmer Biomet, a global orthopedic giant, in 2022. Initially, it operated both spinal and dental businesses. To focus on its core operations, the company divested its spinal business in 2023 and transformed itself into a pure-play dental enterprise. Its core business covers dental implants, biomaterials and innovative digital surgical planning software, boasting a solid position in the global market. This acquisition is regarded as a crucial step for ZimVie to realize capital revaluation of its value following its strategic transformation.
The acquirer, ARCHIMED, is a private equity firm managing approximately €8 billion in assets, with a long-standing focus on the medical technology sector. It values ZimVie's brand foundation in the high-end dental implant market and the growth potential of its digital dental solutions. After privatization, ZimVie is expected to secure more patient capital and operational support, enabling it to increase investment in innovative fields such as digital dentistry and immediate implantology, and accelerate its global market expansion.

ARCHIMED acquires ZimVie at a premium (3)

This transaction reflects a prevailing trend in the medical technology industry: medium-sized enterprises with proprietary technologies yet facing growth pressures in the public market are emerging as key targets for private equity capital's integration and value reshaping initiatives. Privatization will grant ZimVie greater flexibility in strategic decision-making, facilitating its focus on long-term development.